Bharat Biotech’s ROTAVAC 5D receives WHO pre-qualification

It's the only rotavirus vaccine in the world to be delivered in a 0.5 ml dose volume

Bharat Biotech has announced that the World Health Organization (WHO) has awarded pre-qualification to its rotavirus vaccine, ROTAVAC 5D. The new variant of ROTAVAC, ROTAVAC 5D, is a rotavirus vaccine formulation that can be administered without a buffer. Its low dose volume (0.5 mL) facilitates easy vaccine logistics, cold chain management, and low biomedical waste disposal post-vaccination. It is used for the prevention of rotavirus infection, which is prevalent in infants and young children, the company said in a statement.

WHO pre-qualification enables the procurement of ROTAVAC 5D by the UN agencies namely UNICEF and PAHO. It is a validation of the global quality and safety standards required for pediatric vaccines. WHO prequalification of ROTAVAC 5D will fast-track global access to this life-saving vaccine, it said.

Speaking on the development, Suchitra Ella, Joint Managing Director, Bharat Biotech, said, “ROTAVAC and ROTAVAC 5D are the projects conceived, innovated, and executed in India, in collaboration with Indian and global partners. This is the culmination of a 30-year effort to develop a novel rotavirus vaccine, resulting in a major advancement in rotavirus disease prevention, and reasserts India’s leadership in developing and introducing rotavirus vaccines for the world. Today’s announcement is an important step to further strengthen and fulfill Bharat Biotech’s vision to address neglected diseases and prevent infections that continue to affect millions in the developing world.”

Bharat Biotech developed the first-generation rotavirus vaccine, ROTAVAC, under a Public-Private Partnership with the Department of Biotechnology, Government of India, and 16 other international partners, making it the largest-ever social innovation project for public health. In the developing world, ROTAVAC has been instrumental in addressing deaths due to rotavirus infection. Bharat Biotech has so far supplied more than 250 million doses of ROTAVAC, mentioned the statement.

Tags : #BharatBiotech #Rotovac #Rotovac5d #WHO #WHOPrequalification #smitakumar #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Parental tips for keeping teens safe onlineFebruary 08, 2023
The Symptoms and Causes of Anorexia NervosaFebruary 08, 2023
Pervez Musharraf President of Pakistan died of Amyloidosis, a rare diseaseFebruary 07, 2023
National AIDS Control Program – Importance of knowing HIV statusFebruary 06, 2023
FGM : Let's End the practice that hurts girls and womenFebruary 06, 2023
World Cancer Day - Most prominent cancers of IndiaFebruary 04, 2023
World Cancer Day - Never Give up the HopeFebruary 04, 2023
Salt - Effects of Consuming too much SaltFebruary 03, 2023
India’s mission of eliminating dog-mediated rabies by 2030February 03, 2023
Climate change and healthFebruary 02, 2023
Rheumatoid Arthritis Awareness Day: Let's Create AwarenessFebruary 02, 2023
Importance of early diagnosis and cancer screeningFebruary 01, 2023
Union Budget 2023-2024: What's for Healthcare?February 01, 2023
Nourish You has raised $2million to Invest in R&D and Strengthen its Market Presence.February 01, 2023
Enzene Biosciences has raised $50million to expand in its core market of India and US.January 31, 2023
Enzene Biosciences has raised $50million to expand in its core market of India and US.January 31, 2023
World Leprosy Day 2023 – Act now, End LeprosyJanuary 30, 2023
The Warrior Expedition 32/26: A Mission to Encourage Youths to join Indian ForcesJanuary 30, 2023
Mental health – What’s normal and what’s abnormalJanuary 30, 2023
Big Data in Healthcare and Its BenefitsJanuary 27, 2023